MRTIS TechBio Wins HK IPO Approval

Beijing AI nanomedicine firm wins Hong Kong listing green light.

Chinese regulators have cleared MRTIS TechBio (Beijing) Co., Ltd. to pursue an overseas listing in Hong Kong, a move that formalizes a cross-border path for a homegrown AI-biotech player. The company plans to issue up to 273 million new shares, while 39 existing shareholders will convert roughly 852 million domestic shares into tradable H-shares under a full-circulation scheme, according to Chinese regulatory filings.

Founded in 2020 by Dr. Hongmin Chen—an active member of the U.S. National Academy of Engineering—and MIT-affiliated researchers Caidan Lai and Wenshou Wang, MRTIS runs on an AI-enabled nanomaterial platform called NanoForge. The platform builds a vast database of lipid nanoparticle (LNP) designs—tens of millions of compounds—and targets delivery to eight organs and tissues, including liver, lungs, and immune cells. The company’s lead candidate, MTS-004, is touted as the first AI-enabled formulation drug in China to complete Phase III trials. Another candidate, MTS-105, has received U.S. FDA orphan drug designation and is being developed as a potential first-in-class mRNA-encoded TCE therapy for solid tumors.

Supply chain disclosures reveal MRTIS has already attracted substantial private funding, having raised more than $350 million (about RMB 2.5 billion) from investors such as XtalPi, HongShan, 5Y Capital, and China Life. This financing backdrop underscores the cross-border confidence in China’s AI-enabled biopharma pipeline, even as it faces the usual scrutiny that accompanies aspirational therapies and complex manufacturing platforms.

The listing structure—a mix of new equity and the conversion of a large block of domestic shares into tradable H-shares—highlights how Beijing and Hong Kong regulators are enabling liquidity while preserving a path for strategic control and ownership to remain aligned with domestic policy objectives. The Hong Kong route remains a preferred portal for tech-biotech scaling, offering international access without some of the regulatory frictions that can accompany a mainland float.

Industry watchers will be watching MRTIS closely for two reasons. First, the combination of an AI-driven formulation platform with an AI-enabled pipeline at the Phase III stage provides a relatively rare value inflection: credible early-stage data meets a visible regulatory milestone. Second, the cross-border funding and cross-border listing dynamic—where Chinese biotech firms tap HK liquidity while maintaining close ties to domestic science hubs—illustrates how China’s innovation agenda translates to the factory-floor level, with capital markets acting as the interface.

Practical takeaways for practitioners tracking this story include: the Phase III status of MTS-004 makes MRTIS’s valuation sensitive to regulatory signals around AI-based formulations and formulation-specific risk, not just the usual biotech milestones; the full-circulation scheme for converting domestic shares to H-shares implies a staged unlock of liquidity that could influence near-term stock dynamics in HK; and the collaboration model—anchored by top-tier researchers from China and the U.S.—will be a key narrative driver for investor confidence as MRTIS scales manufacturing and moves toward larger clinical programs. Watch next for updates on the HK listing timetable, any additional regulatory stipulations from the CSRC, and the company’s progress on manufacturing scale-up for LNPs and related components.

In short, MRTIS’s HK filing signals a calibrated bet: that AI-enabled nanomedicine can be scaled for global markets, and that Hong Kong’s capital markets remain a viable conduit for China’s most ambitious biotech ambitions.

Sources

MRTIS TechBio Secures Approval for Hong Kong IPO Filing